Keros Therapeutics Inc — 四半期キャッシュフロー (NASDAQ:KROS) | MetaTrader

チャート全体を表示

Financials

概要明細書統計

総資産 615.89 M784.56 M757.16 M742.78 M338.02 M 負債合計 44.33 M55.69 M50.43 M39.2 M34.89 M 純資産合計 571.55 M728.87 M706.73 M703.58 M303.13 M 負債および純資産合計 615.89 M784.56 M757.16 M742.78 M338.02 M 有利子負債合計 ————— 純負債 —————

ニュース

Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?

KROS: Is the Discount Book Value a Value Trap?

KROS Stock: What to Know About Rinvatercept in DMD

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?

Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

【決算速報】Keros、売上高は予想を下回り、利益は予想を下回る結果に

Keros earnings missed by $0.16, revenue fell short of estimates

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?

Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?

SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD